“…In the different tests, we compared our model with other kind of classifiers like SVM [ [43] and Fuzzy system HFBFS [44]. It resulted in a satisfactory improvement with range around 3% with Leukemia dataset, between 4% and 6% with Lymphoma dataset, between 0.3% and 8% with lung cancer dataset, and more than 10% with Colon cancer dataset.…”